Non-Metastatic Castrate Resistant Prostate Cancer (nmCRPC) usually leads to metastatic prostate cancer and death. There are no approved treatments for nmCRPC. Apalutamide is a taken-by-mouth androgen receptor inhibitor with antitumor activity in CRPC. There’s a much talked and written about clinical trial called, SPARTAN, that investigated how well Apalutamide works on maintaining metastasis-free survival (MFS) in men with nmCRPC. 1207 participated in this trial. pts were randomized. Apalutamide decreased the risk of distant metastasis or death by 72% , with a median metastatic free survival period of 40.5 (given Apalutamide) vs 16.2 months (control group not given Apalutamide). Apalutamide significantly improved median metastatic free survival by 2 years in men with nmCRPC. These results support using Apalutamide in men with nmCRPC.
By Malecare|2018-02-05T18:25:03-05:00February 7th, 2018|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Hormone Therapy, Research, Understanding APC|0 Comments
About the Author: Malecare
Malecare is the world's leading men's cancer support and advocacy nonprofit organization.
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Leave A Comment